GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD¹ from the University of Minnesota Medical School² will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San Diego, CA.